GlassScriptPhysician profile
Fay Gao
NPI 1124446331
$12,992.21
in general payments reported to CMS, 2019-2025
22 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,122 · 2020: $404 · 2021: $48.93 · 2022: $124 · 2023: $735 · 2024: $733 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,998 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200 · Education: $95.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
| Education | $95.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $7,269.60 | 2019-2020 | |
| Boston Scientific Corporation | $2,196.94 | 2019-2025 | General - Dbs |
| Medtronic, INC. | $1,301.08 | 2023-2025 | Percept PC Brainsense, Activa PC |
| Insightec,INC | $446.51 | 2023-2024 | Exablate |
| Abbvie INC. | $358.76 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $277.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $266.32 | 2019-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $174.75 | 2024 | |
| Kyowa Kirin, INC. | $124.77 | 2020 | |
| Genentech, INC. | $112.66 | 2023 | Enspryng |
| Pfizer INC. | $100.57 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $67.94 | 2023-2025 | Rytary, Crexont |
| Genentech USA, INC. | $57.47 | 2024-2025 | Enspryng, Ocrevus Zunovo |
| Neurelis, INC. | $49.38 | 2024-2025 | Valtoco |
| Abbott Laboratories | $48.93 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $28.52 | 2019 | |
| Acorda Therapeutics, INC | $25.81 | 2019 | |
| Cycle Pharmaceuticals INC | $22.79 | 2025 | Bafiertam |
| Vanda Pharmaceuticals INC. | $21.49 | 2025 | Ponvory |
| Horizon Therapeutics Plc | $14.72 | 2023 | Uplizna |
| Amgen INC. | $13.30 | 2024 | Uplizna |
| Alexion Pharmaceuticals, INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fay Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.